References
- Dementia statistics. Available from: http://www.alz.co.uk/research/statistics.
- World Alzheimer Report 2015, The global impact of dementia, an analysis of prevalence, incidence, cost and trends. Available from: http://www.alz.co.uk/research/WorldAlzheimerReport2015-sheet.pdf.
- Schneider, L.S., Mangialasche F., et al. Clinical trials and late-stage drug development for Alzheimer’s disease: an appraisal from 1984 to 2014. J Intern Med. 2014;27(3):251–283.
- Fan LY, Chiu MJ. Combotherapy and current concepts as well as future strategies for the treatment of Alzheimer’s disease. Neuropsychiatr Dis Treat. 2014;10:439–451.
- Bloom GS. Amyloid-beta and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol. 2014;71(4):505–508.
- Bertram L, Tanzi RE. The genetics of Alzheimer’s disease. Prog Mol Biol Transl Sci. 2012;107:79–100.
- Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol Sci. 1991;12(10):383–388.
- Selkoe DJ. Resolving controversies on the path to Alzheimer’s therapeutics. Nat Med. 2011;17(9):1060–1065.
- Pimplikar SW. Reassessing the amyloid cascade hypothesis of Alzheimer’s disease. Int J Biochem Cell Biol. 2009;41(6):1261–1268.
- Epis R, Marcello E, Gardoni F, et al. Alpha, beta-and gamma-secretases in Alzheimer’s disease. Front Biosci (Schol Ed). 2012;4:1126–1150.
- Tomita T. Secretase inhibitors and modulators for Alzheimer’s disease treatment. Expert Rev Neurother. 2009;9(5):661–679.
- Banks WA. Drug delivery to the brain in Alzheimer’s disease: consideration of the blood-brain barrier. Adv Drug Deliv Rev. 2012;64(7):629–639.
- Loy C, Schneider L. Galantamine for Alzheimer’s disease and mild cognitive impairment. Cochrane Database Syst Rev. 2006;1:CD001747.
- Birks J, Grimley Evans J, Iakovidou V, et al. Rivastigmine for Alzheimer’s disease. Cochrane Database Syst Rev. 2009;2:CD001191.
- Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer’s disease. N Engl J Med. 2012;366(10):893–903.
- Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 2006;1:CD005593.
- Matsunaga S, Kishi T, Iwata N. Combination therapy with cholinesterase inhibitors and memantine for Alzheimer’s disease: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2015;18:5.
- Wicke K, Haupt A, Bespalov A. Investigational drugs targeting 5-HT6 receptors for the treatment of Alzheimer’s disease. Expert Opin Investig Drugs. 2015;24(12):1515–1528.
- Upton N, Chuang TT, Hunter AJ, et al. 5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer’s disease. Neurotherapeutics. 2008;5(3):458–469.
- Arnt J, Bang-Andersen B, Grayson B, et al. Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int J Neuropsychopharmacol. 2010;13(8):1021–1033.
- Wilkinson D, Windfeld K, Colding-Jorgensen E. Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer’s disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2014;13(11):1092–1099.
- Study of Lu AE58054 in patients with mild - moderate Alzheimer’s disease treated with donepezil (STARSHINE). Available from: https://www.clinicaltrials.gov/show/NCT01955161.
- Lu AE58054 in patients with mild-moderate Alzheimer’s disease treated with donepezil (STARBEAM). Available from: https://www.clinicaltrials.gov/show/NCT02006641.
- Lu AE58054 in patients with mild to moderate Alzheimer’s disease treated with an acetylcholinesterase inhibitor (STARBRIGHT). Available from: https://www.clinicaltrials.gov/show/NCT02006654.
- Long-term safety and tolerability of Lu AE58054 as adjunctive treatment to donepezil in patients with mild-moderate Alzheimer’s disease (STAR Extension). Available from: https://www.clinicaltrials.gov/show/NCT02079246.
- De Bruin NM, Van Drimmelen M, Kops M, et al. Effects of risperidone, clozapine and the 5-HT6 antagonist GSK-742457 on PCP-induced deficits in reversal learning in the two-lever operant task in male sprague dawley rats. Behav Brain Res. 2013;244:15–28.
- Callaghan CK, Hok V, Della-Chiesa A, et al. Age-related declines in delayed non-match-to-sample performance (DNMS) are reversed by the novel 5HT6 receptor antagonist SB742457. Neuropharmacology. 2012;63(5):890–897.
- A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer’s disease.; Available from: https://clinicaltrials.gov/show/NCT00710684.
- Study of SB-742457 or Donepezil Versus Placebo in Subjects With Mild-to-moderate Alzheimer’s disease. Available from: https://clinicaltrials.gov/show/NCT00708552.
- Maher-Edwards G, Zvartau-Hind M, Hunter AJ, et al. Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer’s disease. Curr Alzheimer Res. 2010;7(5):374–385.
- Codony X, Vela JM, Ramirez MJ. 5-HT(6) receptor and cognition. Curr Opin Pharmacol. 2011;11(1):94–100.
- Bhattacharya S, Maelicke A, Montag D. Nasal application of the galantamine pro-drug memogain slows down plaque deposition and ameliorates behavior in 5X familial Alzheimer’s disease mice. J Alzheimers Dis. 2015;46(1):123–136.
- Maelicke A, Hoeffle-Maas A, Ludwig J. et al., Memogain is a galantamine pro-drug having dramatically reduced adverse effects and enhanced efficacy. J Mol Neurosci. 2010;40(1–2):135–137.
- Hock C, Maddalena A, Raschig A. et al., Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer’s disease. Amyloid. 2003;10(1):1–6.
- Caccamo A, Fisher A, LaFerla FM. M1 agonists as a potential disease-modifying therapy for Alzheimer’s disease. Curr Alzheimer Res. 2009;6(2):112–117.
- Caccamo A, Oddo S, Billings LM, et al. M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron. 2006;49(5):671–682.
- Fisher A. M1 muscarinic agonists target major hallmarks of Alzheimer’s disease–an update. Curr Alzheimer Res. 2007;4(5):577–580.
- Bodick NC, Offen WW, Levey AI, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol. 1997;54(4):465–473.
- Foster DJ, Choi DL, Conn PJ, et al. Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer’s disease and schizophrenia. Neuropsychiatr Dis Treat. 2014;10:183–191.
- Rare but severe side effects sideline some phase 3 encenicline trials. Available from: http://www.alzforum.org/news/research-news/rare-severe-side-effects-sideline-some-phase-3-encenicline-trials.
- Puri V, Wang X, Vardigan JD, et al. The selective positive allosteric M1 muscarinic receptor modulator PQCA attenuates learning and memory deficits in the Tg2576 Alzheimer’s disease mouse model. Behav Brain Res. 2015;287:96–99.
- Lange HS, Cannon CE, Drott JT, et al. The M1 muscarinic positive allosteric modulator PQCA improves performance on translatable tests of memory and attention in rhesus monkeys. J Pharmacol Exp Ther. 2015;355(3):442–450.
- Efficacy and safety of MK-7622 as adjunct therapy in participants with Alzheimer’s disease (MK-7622-012). Available from: https://www.clinicaltrials.gov/show/NCT01852110.
- Villard V, Espallergues J, Keller E, et al. Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigma 1 (sigma1) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative. J Psychopharmacol. 2011;25(8):1101–1117.
- Lahmy V, Meunier J, Malmstrom S, et al. Blockade of Tau hyperphosphorylation and Abeta(1)(-)(4, 2) generation by the aminotetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic and sigma(1) receptor agonist, in a nontransgenic mouse model of Alzheimer’s disease. Neuropsychopharmacology. 2013;38(9):1706–1723.
- Phase 2a dose finding, PK/PD and 12 month exploratory efficacy study of ANAVEX2-73 in patients with Alzheimer’s disease. Available from: https://clinicaltrials.gov/show/NCT02244541.
- 12 month data of anavex 2 73 in a phase 2a study in mild to moderate alzheimers disease patients. Available from: http://www.anavex.com/anavex-life-sciences-announces-12-month-data-of-anavex-2-73-in-a-phase-2a-study-in-mild-to-moderate-alzheimers-disease-patients/.
- Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6(8):734–746.
- Sperling R, Mormino E, Johnson K. The evolution of preclinical Alzheimer’s disease: implications for prevention trials. Neuron. 2014;84(3):608–622.
- Progress of mild Alzheimer’s disease in participants on solanezumab versus placebo (EXPEDITION 3). Available from: https://www.clinicaltrials.gov/show/NCT01900665.
- Bohrmann B, Baumann K, Benz J, et al. Gantenerumab: a novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta. J Alzheimers Dis. 2012;28(1):49–69.
- A long-term safety extension study of studies ABE4869g and ABE4955g in patients with mild to moderate Alzheimer’s disease treated with crenezumab. . Available from: http://clinicaltrials.gov/ct2/show/NCT01723826.
- Sevigny J, Aducanumab (BIIB037), An anti-amyloid beta monoclonal antibody in patients with prodromal or mild Alzheimer’s disease: interim results of a randomized, double-blind, placebo-controlled, phase IB study, Alzheimer’s Association International Conference 2015. 2015: Washington, D.C.
- A study to evaluate safety, tolerability, and efficacy of BAN2401 in subjects with early Alzheimer’s disease. Available from: https://clinicaltrials.gov/ct2/show/NCT01767311.
- SAD/MAD Study to assess safety, Tolerability, PK & PD of MEDI1814 in subjects with mild-moderate Alzheimer’s disease.; Available from: https://clinicaltrials.gov/ct2/show/NCT02036645.
- A study of LY3002813 in participants with memory damage due to Alzheimer’s disease (AD) or AD. Available from: https://clinicaltrials.gov/ct2/show/NCT02624778.
- ACI-24, Active Alzheimer’s disease immunotherapy targeting Abeta. Available from: http://acimmune.com/en/ad-treatment-and-prevention/#aci-24.
- Winblad B, Andreasen N, Minthon L, et al. Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer’s disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol. 2012;11(7):597–604.
- Evaluate the safety, tolerability, immunogenicity and efficacy of UB-311 in mild Alzheimer’s disease (AD) patients. Available from: https://clinicaltrials.gov/ct2/show/NCT02551809.
- A study to evaluate the safety and tolerability of a new drug named Lu AF20513 in patients with mild Alzheimer’s disease. Available from: https://clinicaltrials.gov/ct2/show/NCT02388152.
- A phase Ib multicenter, double-blind, randomized, placebo-controlled study of the safety, tolerability and immunogenicity of ACI-35 in patients with mild to moderate Alzheimer’s disease. Available from: http://apps.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN13033912.
- 24 months safety and efficacy study of AADvac1 in patients with mild Alzheimer’s disease (ADAMANT). Available from: https://www.clinicaltrials.gov/ct2/show/NCT02579252.
- Vassar R, Kuhn PH, Haass C, et al. Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects. J Neurochem. 2014;130(1):4–28.
- Mangialasche F, Solomon A, Winblad B, et al. Alzheimer’s disease: clinical trials and drug development. Lancet Neurol. 2010;9(7):702–716.
- May PC, Dean RA, Lowe SL, et al. Robust central reduction of amyloid-beta in humans with an orally available, non-peptidic beta-secretase inhibitor. J Neurosci. 2011;31(46):16507–16516.
- Mikulca JA, Nguyen V, Gajdosik DA, et al. Potential novel targets for Alzheimer pharmacotherapy: II. Update on secretase inhibitors and related approaches. J Clin Pharm Ther. 2014;39(1):25–37.
- An extension study to evaluate the long-term safety and tolerability of JNJ-54861911 in participants in the early Alzheimer’s disease spectrum. Available from: https://clinicaltrials.gov/ct2/show/NCT02406027.
- An efficacy and safety study of JNJ-54861911 in participants who are asymptomatic at risk for developing Alzheimer’s Dementia. Available from: https://clinicaltrials.gov/ct2/show/NCT02569398.
- A study of CAD106 and CNP520 versus placebo in participants at risk for the onset of clinical symptoms of Alzheimer’s disease (Generation). Available from: https://clinicaltrials.gov/ct2/show/NCT02565511.
- Langbaum JB, Hendrix S, Ayutyanont N, et al. Establishing composite cognitive endpoints for use in preclinical Alzheimer’s disease trials. J Prev Alzheimers Dis. 2015;2(1):2–3.
- AstraZeneca and Lilly announce alliance to develop and commercialise BACE inhibitor AZD3293 for Alzheimer’s disease. Available from: https://www.astrazeneca.com/our-company/media-centre/press-releases/2014/astrazeneca-lilly-bace-inhibitor-azd3293-Alzheimers-Disease-16092014.html.
- An efficacy and safety study of LY3314814 in Early Alzheimer’s disease (AMARANTH). Available from: https://clinicaltrials.gov/ct2/show/NCT02245737.
- Efficacy and safety trial of verubecestat (MK-8931) in participants with prodromal Alzheimer’s disease (MK-8931-019) (APECS). Available from: https://www.clinicaltrials.gov/show/NCT01953601.
- An efficacy and safety trial of verubecestat (MK-8931) in mild to moderate Alzheimer’s disease (P07738) (EPOCH). Available from: https://clinicaltrials.gov/ct2/show/NCT01739348https://clinicaltrials.gov/ct2/show/NCT01739348.
- Merck Announces EPOCH Study of Verubecestat for the Treatment of People with Mild to Moderate Alzheimer’s disease to Stop for Lack of Efficacy. Available from: http://investors.merck.com/news/press-release-details/2017/Merck-Announces-EPOCH-Study-of-Verubecestat-for-the-Treatment-of-People-with-Mild-to-Moderate-Alzheimers-Disease-to-Stop-for-Lack-of-Efficacy/default.aspx#sthash.32ByHlbX.dpuf.
- An efficacy and safety trial of verubecestat (MK-8931) in mild to moderate Alzheimer’s disease (P07738) (EPOCH). Available from: https://www.clinicaltrials.gov/show/NCT01739348.
- Bai XC, Yan C, Yang G, et al. An atomic structure of human gamma-secretase. Nature. 2015;525(7568):212–217.
- Green RC, Schneider LS, Amato DA, et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer Disease: a randomized controlled trial. Jama. 2009;302(23):2557–2564.
- Crump CJ, Castro SV, Wang F, et al. BMS-708,163 targets presenilin and lacks notch-sparing activity. Biochemistry. 2012;51(37):7209–7211.
- Doody RS, Raman R, Farlow M, et al. A phase 3 trial of semagacestat for treatment of Alzheimer’s disease. N Engl J Med. 2013;369(4):341–350.
- Bursavich MG, Harrison BA, Blain JF. Gamma secretase modulators: new Alzheimer’s drugs on the horizon? J Med Chem. 2016;59(16):7389–7409.
- Crump CJ, Johnson DS, Li YM. Development and mechanism of gamma-secretase modulators for Alzheimer’s disease. Biochemistry. 2013;52(19):3197–3216.
- Fu HJ, Liu B, Frost JL, et al. Amyloid-beta immunotherapy for Alzheimer’s disease. CNS Neurol Disord Drug Targets. 2010;9(2):197–206.
- Wiessner C, Wiederhold KH, Tissot AC, et al. The second-generation active Abeta immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci. 2011;31(25):9323–9331.
- Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer Disease. Nat Med. 2000;6(8):916–919.
- Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-Disease-like pathology in the PDAPP mouse. Nature. 1999;400(6740):173–177.
- Wilcock DM, Colton CA. Anti-amyloid-beta immunotherapy in Alzheimer’s disease: relevance of transgenic mouse studies to clinical trials. J Alzheimers Dis. 2008;15(4):555–569.
- Gilman S, Koller M, Black RS, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005;64(9):1553–1562.
- Moreth J, Mavoungou C, Schindowski K. Passive anti-amyloid immunotherapy in Alzheimer’s disease: what are the most promising targets? Immun Ageing. 2013;10(1):18.
- Johnson & Johnson Announces Discontinuation of Phase 3 Development of Bapineuzumab Intravenous (IV) in Mild-to-moderate Alzheimer’s disease. Available from: http://www.investor.jnj.com/releasedetail.cfm?ReleaseID=698466.
- Sperling R, Salloway S, Brooks DJ, et al. Amyloid-related imaging abnormalities in patients with Alzheimer’s disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol. 2012;11(3):241–249.
- Matthews G,BV. Independent analysis of solanezumab provides evidence that compound may remove amyloid from brain in Alzheimer’s disease. 2012; Available from: http://www.fiercebiotech.com/press-releases/independent-analysis-solanezumab-provides-evidence-compound-may-remove-amyl.
- A Study of LY2599666 in healthy participants and participants with mild cognitive impairment or Alzheimer’s disease (AD). Available from: https://clinicaltrials.gov/ct2/show/NCT02614131.
- Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):280–292.
- Clinical trial of Solanezumab for older individuals who may be at risk for memory loss (A4). Available from: https://clinicaltrials.gov/ct2/show/NCT02008357.
- A study to evaluate the efficacy and safety of MABT5102A in patients with mild to moderate Alzheimer’s disease (ABBY). Available from: https://clinicaltrials.gov/ct2/show/NCT01343966.
- Reiman EM, L.J., Fleisher AS, et al. Alzheimer’s Preven¬tion Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis. 2011;26(Suppl 3):321–329.
- Ostrowitzki S, Deptula D, Thurfjell L, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol. 2012;69(2):198–207.
- A study of gantenerumab in patients with mild Alzheimer disease. Available from: https://www.clinicaltrials.gov/show/NCT02051608.
- Dominantly inherited Alzheimer network trial: an opportunity to prevent dementia. a study of potential disease modifying treatments in individuals at risk for or with a type of early onset Alzheimer’s disease caused by a genetic mutation. (DIAN-TU). Available from: https://www.clinicaltrials.gov/ct2/show/NCT01760005.
- DIAN observational study. Available from: http://www.dian-info.org/.
- Media release, basel, 19 december 2014, roche provides update on gantenerumab development programme. Available from: http://www.roche.com/media/store/releases/med-cor-2014-12-19b.htm.
- Reardon S. Antibody drugs for Alzheimer’s show glimmers of promise. Nature. 2015;523(7562):509–510.
- Sevigny J, Chiao P, Bussiere T, et al. The antibody aducanumab reduces Abeta plaques in Alzheimer’s disease. Nature. 2016;537(7618):50–56.
- Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol. 2010;9(11):1118–1127.
- Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):270–279.
- Biogen will push Alzheimer’s drug to phase 3. Available from: http://www.bloomberg.com/news/articles/2014-12-02/biogen-rises-on-results-of-early-stage-Alzheimer-s-drug-trial.
- 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer’s disease (ENGAGE). Available from: https://clinicaltrials.gov/ct2/show/NCT02477800.
- 221AD302 phase 3 study of aducanumab (BIIB037) in early Alzheimer’s disease (EMERGE). Available from: https://clinicaltrials.gov/ct2/show/NCT02484547.
- Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology. 2003;61(1):46–54.
- Schneeberger A, Mandler M, Otawa O, et al. Development of AFFITOPE vaccines for Alzheimer’s disease (AD)–from concept to clinical testing. J Nutr Health Aging. 2009;13(3):264–267.
- Arai H HS, Tamotsu Y, Lobello K, et al., Safety, tolerability, and immunogenicity of an immunotherapeutic vaccine (vanutide cridificar [ACC-001]) and the QS-21 adjuvant in Japanese subjects with mild to moderate Alzheimer’s disease: a phase 2a, multicenter, randomized, adjuvant- and placebo-controlled,multiple-ascending-dose study. International Conference on Alzheimer’s disease (ICAD)2013: Boston, MA, USA.
- Mandler M SW, Mattner F. Development of AFFITOPE Alzheimer vaccines: results of phase I studies with AD01 and AD02 [abstract]. Alzheimers Dement. 2011;7:S793.
- Clinical- and immunological activity, safety and tolerability of different doses /Formulations of AFFITOPE AD02 in early Alzheimer’s disease. Available from: https://clinicaltrials.gov/ct2/show/NCT01117818.
- Mandler M, Santic R, Weninger H.et al. The Mimovax Vaccine: a Novel Alzheimer Treatment Strategy Targeting Truncated Aβ40/42 by Active Immunization [Abstract]. Alzheimers Dement. 2009;5:114.
- Follow-up study to evaluate long-term safety and tolerability of immunization with AD03 applied during AFF005A. Available from: https://clinicaltrials.gov/ct2/show/NCT01568086.
- Wang CY, Finstad CL, Walfield AM, et al. Site-specific UBITh amyloid-beta vaccine for immunotherapy of Alzheimer’s disease. Vaccine. 2007;25(16):3041–3052.
- Study to evaluate safety, tolerability and immunogenicity of vaccine (UB 311) in subjects with Alzheimer’s disease. Available from: https://clinicaltrials.gov/ct2/show/NCT00965588.
- Davtyan H, Ghochikyan A, Petrushina I, et al. Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer’s disease: prelude to a clinical trial. J Neurosci. 2013;33(11):4923–4934.
- Holmes C, Boche D, Wilkinson D, et al. Long-term effects of Abeta42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008;372(9634):216–223.
- Galimberti D, Scarpini E. Disease-modifying treatments for Alzheimer’s disease. Ther Adv Neurol Disord. 2011;4(4):203–216.
- Pedersen JT, Sigurdsson EM. Tau immunotherapy for Alzheimer’s disease. Trends Mol Med. 2015;21(6):394–402.
- Hickman DT, Lopez-Deber MP, Ndao DM, et al. Sequence-independent control of peptide conformation in liposomal vaccines for targeting protein misfolding diseases. J Biol Chem. 2011;286(16):13966–13976.
- Theunis C, Crespo-Biel N, Gafner V, et al. Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy. Plos One. 2013;8(8):e72301.
- AD Treatment and Prevention. Available from: http://www.acimmune.com/en/ad-treatment-and-prevention/.
- Troquier L, Caillierez R, Burnouf S, et al. Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach. Curr Alzheimer Res. 2012;9(4):397–405.
- Collin L, Bohrmann B, Gopfert U, et al. Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer’s disease. Brain. 2014;137(Pt 10):2834–2846.
- A Study of RO6926496 in Healthy Volunteers. Available from: https://clinicaltrials.gov/ct2/show/NCT02281786.
- Product development portfolio. Available from: http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm.
- Wischik CM, Edwards PC, Lai RY, et al. Selective inhibition of Alzheimer Disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci U S A. 1996;93(20):11213–11218.
- Crowe A, James MJ, Lee VM, et al. Aminothienopyridazines and methylene blue affect Tau fibrillization via cysteine oxidation. J Biol Chem. 2013;288(16):11024–11037.
- Congdon EE, Wu JW, Myeku N, et al. Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo. Autophagy. 2012;8(4):609–622.
- Wen Y, Li W, Poteet EC, et al. Alternative mitochondrial electron transfer as a novel strategy for neuroprotection. J Biol Chem. 2011;286(18):16504–16515.
- Medina DX, Caccamo A, Oddo S. Methylene blue reduces abeta levels and rescues early cognitive deficit by increasing proteasome activity. Brain Pathol. 2011;21(2):140–149.
- Deiana S, Harrington CR, Wischik CM, et al. Methylthioninium chloride reverses cognitive deficits induced by scopolamine: comparison with rivastigmine. Psychopharmacology (Berl). 2009;202(1–3):53–65.
- Riha PD, Rojas JC, Gonzalez-Lima F. Beneficial network effects of methylene blue in an amnestic model. Neuroimage. 2011;54(4):2623–2634.
- Stack C, Jainuddin S, Elipenahli C. et al., Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity. Hum Mol Genet. 2014;23(14):3716–3732.
- Hochgrafe K, Sydow A, Matenia D, et al. Preventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau. Acta Neuropathol Commun. 2015;3:25.
- Wischik C, Staff R. Challenges in the conduct of disease-modifying trials in AD: practical experience from a phase 2 trial of Tau-aggregation inhibitor therapy. J Nutr Health Aging. 2009;13(4):367–369.
- Baddeley TC, McCaffrey J, Storey JM, et al. Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer’s disease. J Pharmacol Exp Ther. 2015;352(1):110–118.
- Safety and efficacy study evaluating TRx0237 in subjects with mild Alzheimer’s disease. Available from: https://www.clinicaltrials.gov/show/NCT01689233.
- Safety and efficacy study evaluating TRx0237 in subjects with mild to moderate Alzheimer’s disease. Available from: https://www.clinicaltrials.gov/show/NCT01689246.
- Gauthier S, Feldman HH, et al. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer’s disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet. 2016 Dec 10;388(10062):2873–2884.
- Lund H, Gustafsson E, Svensson A, et al. MARK4 and MARK3 associate with early tau phosphorylation in Alzheimer’s disease granulovacuolar degeneration bodies. Acta Neuropathol Commun. 2014;2:22.
- Zhang B, Carroll J, Trojanowski JQ, et al. The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. J Neurosci. 2012;32(11):3601–3611.
- Varghese M, Ho L, Wang J, et al. Green coffee as a novel agent for Alzheimer’s disease prevention by attenuating diabetes. Translational Neuroscience. 2014;5(2):111–116.
- Rohena CC, Mooberry SL. Recent progress with microtubule stabilizers: new compounds, binding modes and cellular activities. Nat Prod Rep. 2014;31(3):335–355.
- Corbett A, Williams G, Ballard C. Drug repositioning: an opportunity to develop novel treatments for Alzheimer’s disease. Pharmaceuticals (Basel). 2013;6(10):1304–1321.
- Corbett A, Pickett J, Burns A, et al. Drug repositioning for Alzheimer’s disease. Nat Rev Drug Discov. 2012;11(11):833–846.
- Zhao W, Wang J, Ho L, et al. Identification of antihypertensive drugs which inhibit amyloid-beta protein oligomerization. J Alzheimers Dis. 2009;16(1):49–57.
- Bachmeier C, Beaulieu-Abdelahad D, Mullan M, et al. Selective dihydropyiridine compounds facilitate the clearance of beta-amyloid across the blood-brain barrier. Eur J Pharmacol. 2011;659(2–3):124–129.
- Li N, Liu B, Dluzen DE, et al. Protective effects of ginsenoside Rg2 against glutamate-induced neurotoxicity in PC12 cells. J Ethnopharmacol. 2007;111(3):458–463.
- Paris D, Bachmeier C, Patel N, et al. Selective antihypertensive dihydropyridines lower Abeta accumulation by targeting both the production and the clearance of Abeta across the blood-brain barrier. Mol Med. 2011;17(3–4):149–162.
- Paris D, Quadros A, Humphrey J, et al. Nilvadipine antagonizes both Abeta vasoactivity in isolated arteries, and the reduced cerebral blood flow in APPsw transgenic mice. Brain Res. 2004;999(1):53–61.
- Iwasaki K, Egashira N, Takagaki Y, et al. Nilvadipine prevents the impairment of spatial memory induced by cerebral ischemia combined with beta-amyloid in rats. Biol Pharm Bull. 2007;30(4):698–701.
- A Phase III Trial of Nilvadipine to Treat Alzheimer’s disease (NILVAD). Available from: https://clinicaltrials.gov/ct2/show/NCT02017340.
- Gold M, Alderton C, Zvartau-Hind M, et al. Rosiglitazone monotherapy in mild-to-moderate Alzheimer’s disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord. 2010;30(2):131–146.
- Landreth G, Jiang Q, Mandrekar S, et al. PPARgamma agonists as therapeutics for the treatment of Alzheimer’s disease. Neurotherapeutics. 2008;5(3):481–489.
- Biomarker qualification for risk of Mild Cognitive Impairment (MCI) Due to Alzheimer’s disease (AD) and safety and efficacy evaluation of pioglitazone in delaying its onset (TOMMORROW). Available from: https://clinicaltrials.gov/ct2/show/NCT01931566.
- Marcade M, Bourdin J, Loiseau N, et al. Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing. J Neurochem. 2008;106(1):392–404.
- Desire L, Peillon H MM, Drouin D, et al. Clinical trials of EHT 0202, a neuroprotective and procognitive alpha-secretase stimulator for Alzheimer’s disease. 2009;4:5:255-256.
- A study assessing bryostatin in the treatment of moderately severe to severe Alzheimer’s disease. Available from: https://clinicaltrials.gov/ct2/show/NCT02431468.
- Old drug offers new hope to treat Alzheimer’s disease. Available from: http://www.sciencedaily.com/releases/2015/09/150921133646.htm.
- Chumakov I, Nabirotchkin S., et al. Combining two repurposed drugs as a promising approach for Alzheimer's disease therapy. Scientific Reports 5, Article number: 7608 (2015). Available from: http://www.nature.com/articles/srep07608.
- Genistein as a possible treatment for Alzheimer’s disease. (GENISTEÍNA_2). Available from: https://clinicaltrials.gov/ct2/show/NCT01982578.
- Remington R, Chan A, Paskavitz J, et al. Efficacy of a vitamin/nutriceutical formulation for moderate-stage to later-stage Alzheimer’s disease: a placebo-controlled pilot study. Am J Alzheimers Dis Other Demen. 2009;24(1):27–33.
- Mospan CM. Are statins protective or harmful to cognitive function? Jaapa. 2016;29(1):11–12.
- Feldman HH, Doody RS, Kivipelto DR. et al. Randomized controlled trial of natorvastatin in mild to moderate Alzheimern disease: lEADe. Neurology. 2010;74(12):956–964.
- The clinical study of pitavastatin treatment for group of mild to moderate Alzheimer’s disease (PIT-ROAD). Available from: http://clinicaltrials.gov/ct2/show/NCT00548145.
- Trial of simvastatin in amnestic mild cognitive impairment (MCI) patients (SIMaMCI). Available from: http://clinicaltrials.gov/ct2/show/NCT00842920.
- Johanssen T, Suphantarida N, Donnelly PS, et al. PBT2 inhibits glutamate-induced excitotoxicity in neurons through metal-mediated preconditioning. Neurobiol Dis. 2015;81:176–185.
- Prana Biotechnology announces top line results of Phase 2 IMAGINE trial of PBT2 in Alzheimer’s disease. Available from: http://pranabio.com/news/prana-biotechnology-announces-top-line-results-phase-2-imagine-trial-pbt2-Alzheimers-disease/#.WRnlFWnyviw.
- Chen S, Wang JM, Irwin RW, et al. Allopregnanolone promotes regeneration and reduces beta-amyloid burden in a preclinical model of Alzheimer’s disease. Plos One. 2011;6(8):e24293.
- Wang JM, Singh C, Liu L, et al. Allopregnanolone reverses neurogenic and cognitive deficits in mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A. 2010;107(14):6498–6503.
- Zhang P, Xie MQ, Ding YQ, et al. Allopregnanolone enhances the neurogenesis of midbrain dopaminergic neurons in APPswe/PSEN1 mice. Neuroscience. 2015;290:214–226.
- Allopregnanolone for mild cognitive impairment due to Alzheimer’s disease or mild AD. Available from: https://clinicaltrials.gov/ct2/show/NCT02221622.
- Shi JQ, Shen W, Chen J, et al. Anti-TNF-alpha reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cell in the APP/PS1 transgenic mouse brains. Brain Res. 2011;1368:239–247.
- Butchart J, Brook L, Hopkins V, et al. Etanercept in Alzheimer Disease: A randomized, placebo-controlled, double-blind, phase 2 trial. Neurology. 2015;84(21):2161–2168.
- Frost JL, Le KX, Cynis H, et al. Pyroglutamate-3 amyloid-beta deposition in the brains of humans, non-human primates, canines, and Alzheimer Disease-like transgenic mouse models. Am J Pathol. 2013;183(2):369–381.
- Morawski M, Schilling S, Kreuzberger M, et al. Glutaminyl cyclase in human cortex: correlation with (pGlu)-amyloid-beta load and cognitive decline in Alzheimer’s disease. J Alzheimers Dis. 2014;39(2):385–400.
- Safety and Tolerability of PQ912 in subjects with early Alzheimer’s disease (SAPHIR). Available from: https://clinicaltrials.gov/ct2/show/NCT02389413.
- A Phase 2A Multicenter, Randomized, Double Blind, Placebo-Controlled, Parallel-Group Safety and Tolerability Trial of PQ912 in Subjects with early Alzheimer’s Disease. Available from: https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001967-11/NL.
- Jack CR Jr., Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207–216.
- Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med. 2012;367(9):795–804.
- Bateman RJ, Aisen PS, De Strooper B, et al. Autosomal-dominant Alzheimer’s disease: a review and proposal for the prevention of Alzheimer’s disease. Alzheimers Res Ther. 2011;3(1):1.
- Duyckaerts C, Potier MC, Delatour B. Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathol. 2008;115(1):5–38.
- Morris GP, Clark IA, Vissel B. Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer’s disease. Acta Neuropathol Commun. 2014;2:135.
- Chetelat G, La Joie R, Villain N, et al. Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer’s disease. Neuroimage Clin. 2013;2:356–365.
- Rollin-Sillaire A, Breuilh L, Salleron J, et al. Reasons that prevent the inclusion of Alzheimer’s disease patients in clinical trials. Br J Clin Pharmacol. 2013;75(4):1089–1097.
- Morris JC. Early-stage and preclinical Alzheimer Disease. Alzheimer Dis Assoc Disord. 2005;19(3):163–165.
- Luo J, Lee SH, VandeVrede L, et al. A multifunctional therapeutic approach to disease modification in multiple familial mouse models and a novel sporadic model of Alzheimer’s disease. Mol Neurodegener. 2016;11:35.